ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Bought by Northern Trust Corp

Northern Trust Corp increased its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 9.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 204,345 shares of the specialty pharmaceutical company's stock after acquiring an additional 16,820 shares during the quarter. Northern Trust Corp owned approximately 0.97% of ANI Pharmaceuticals worth $11,296,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in ANIP. Barclays PLC grew its holdings in ANI Pharmaceuticals by 1,681.2% in the third quarter. Barclays PLC now owns 143,033 shares of the specialty pharmaceutical company's stock worth $8,534,000 after purchasing an additional 135,003 shares during the last quarter. Franklin Resources Inc. raised its stake in ANI Pharmaceuticals by 6.1% in the third quarter. Franklin Resources Inc. now owns 12,057 shares of the specialty pharmaceutical company's stock valued at $705,000 after buying an additional 691 shares during the last quarter. Assenagon Asset Management S.A. boosted its holdings in ANI Pharmaceuticals by 67.4% in the fourth quarter. Assenagon Asset Management S.A. now owns 311,617 shares of the specialty pharmaceutical company's stock worth $17,226,000 after acquiring an additional 125,438 shares in the last quarter. SG Americas Securities LLC purchased a new stake in ANI Pharmaceuticals during the 4th quarter worth approximately $544,000. Finally, Exchange Traded Concepts LLC grew its position in ANI Pharmaceuticals by 2.6% during the 4th quarter. Exchange Traded Concepts LLC now owns 12,366 shares of the specialty pharmaceutical company's stock worth $684,000 after purchasing an additional 310 shares during the last quarter. 76.05% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at ANI Pharmaceuticals

In related news, VP Meredith Cook sold 400 shares of ANI Pharmaceuticals stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $63.33, for a total transaction of $25,332.00. Following the transaction, the vice president now owns 80,545 shares in the company, valued at approximately $5,100,914.85. This trade represents a 0.49% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Ori Gutwerg sold 881 shares of the company's stock in a transaction that occurred on Thursday, May 15th. The shares were sold at an average price of $60.07, for a total value of $52,921.67. Following the completion of the transaction, the senior vice president now owns 89,897 shares in the company, valued at $5,400,112.79. This represents a 0.97% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 7,681 shares of company stock valued at $468,698 over the last 90 days. 11.10% of the stock is currently owned by corporate insiders.

ANI Pharmaceuticals Price Performance

ANI Pharmaceuticals stock traded down $1.81 during midday trading on Thursday, reaching $57.27. The company had a trading volume of 358,437 shares, compared to its average volume of 301,573. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. ANI Pharmaceuticals, Inc. has a 12-month low of $52.50 and a 12-month high of $77.00. The company has a market capitalization of $1.24 billion, a P/E ratio of -104.13 and a beta of 0.56. The firm's fifty day simple moving average is $66.62 and its 200-day simple moving average is $60.80.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last released its earnings results on Friday, May 9th. The specialty pharmaceutical company reported $1.70 earnings per share for the quarter, beating the consensus estimate of $1.37 by $0.33. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The business had revenue of $197.12 million for the quarter, compared to the consensus estimate of $179.75 million. During the same quarter last year, the business posted $0.82 earnings per share. The business's quarterly revenue was up 43.4% compared to the same quarter last year. As a group, equities analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on ANIP. Guggenheim reaffirmed a "buy" rating and issued a $86.00 price target on shares of ANI Pharmaceuticals in a report on Monday, May 12th. HC Wainwright reiterated a "buy" rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research note on Monday, March 17th. Wall Street Zen cut shares of ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Thursday, April 24th. Jefferies Financial Group started coverage on shares of ANI Pharmaceuticals in a report on Friday, March 14th. They issued a "buy" rating and a $80.00 price target on the stock. Finally, JPMorgan Chase & Co. assumed coverage on ANI Pharmaceuticals in a research report on Wednesday, March 12th. They set an "overweight" rating and a $85.00 price target on the stock. One analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $80.13.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.